Celea Therapeutics’ $180M financing will support a Phase 3 IPF drug trial comparing deupirfenidone with Esbriet.

Researchers have found that a decrease in scar-generating cell death called ferroptosis may be a mechanism that drives IPF.

GRI Bio‘s experimental oral therapy GRI-0621 (tazarotene) has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF) ...

My husband, Donnie, suffered from gastroesophageal reflux disease (GERD) for several years before the onset of his lung issues, and we were surprised to learn of the connection between GERD and ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google I recently received my first Rituxan (rituximab) infusion. Most ...

Familial pulmonary fibrosis (FPF) makes up a notable portion of all cases of interstitial lung disease, disorders marked by scarring in the lungs, and tends to appear differently from non-familial ...

Storytelling is a learning tool as old as time. History is made up of eyewitness accounts and recollections of a certain time or place, often augmented by official records. I’ve seen discussions ...

PF patients often notice breathlessness when exercising or exerting themselves physically, but as the disease progresses, dyspnea begins to occur even when engaging in simple tasks such as walking, ...

Pulmonary fibrosis (PF) is characterized by scarring, or fibrosis, in the lungs. Scar tissue development can interfere with the lungs’ ability to deliver oxygen to the bloodstream, as well as with ...